摘要
目的：观察全反式维甲酸(ATRA)与化疗交替治疗急性早幼粒细胞白血病(APL)的长期疗效。方法：对17例经ATRA治疗取得完全缓解(CR)的APL患者，采用ATRA与化疗交替方案进行治疗。在治疗6个月以后，采用血细胞短期培养G显带技术进行染色体核型分析，RT-PCR技术检测PML-RARα融合基因，流式细胞术(FCM)检测CD13^+CD45dim细胞和CD33^+CD45^dim智细胞，监测t(15；17)染色体异位、PML-RARα融合基因以及CD13^+CD45^dim、细胞和CD13^+CD45^dim细胞变化情况。结果：随访15个月-70个月(中位数36个月)。白血病复发3例，复发率17．65％，总生存率(OS)94．12％，t(15；17)染色体异位、PML-RARα融合基因和FCM检测MRD转阴率分别为23．53％、29．41％和23．53％。结论：APL CR后采用ATRA与化疗交替治疗，可以较好地减少或消除APL患者体内的残存白血病细胞，减少白血病的复发率，延长患者的生存期，提高APL的临床治愈率。
Objective:In order to observe the clinical long - time outcome of treatment of acute promyelocytic leukemia(APL)with all - trans retinoic acid(ATRA)plus chemotherapy.Methods:All the17patients with APL were treated by ATRA plus chemotherapy after complete remission(CR).The chromosome karyotypes were analyzed by G banding technique,PML - RARαfusion genes were detected by RT - PCR,CD +13 CD dim45 cells and CD +33 CD dim45 cells were detected by flow cytometry(FCM)to all the patients after six-month treatment.Results:In the treatment with ATRA plus chemotherapy for15to70months(mean36months),the leukemia relapsing rate was17.65%,the overall survival(OS)was94.12% and the rate of t(15;17)translocation,PML - RARαfusion gene and the minimal residual disease(MRD)detected by FCM becoming negative was23.53%,29.41%and23.53%,respectively.Conclusions:The treatment of ATRA plus chemotherapy for APL may reduce the leukemic clone,decrease the leukemia relapse rate and the patients'survival time and clinical curel rate may be improved.
出处
《白血病．淋巴瘤》
CAS
2004年第1期26-28,共3页
Journal of Leukemia & Lymphoma
